Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda

Vaccine. 2011 Apr 12;29(17):3329-34. doi: 10.1016/j.vaccine.2010.12.122. Epub 2011 Jan 15.

Abstract

We determined impact and cost-effectiveness of pneumococcal and rotavirus vaccination programs among children<5 years of age in Uganda from the public health system perspective. Disease-specific models compared the disease burden and cost with and without a vaccination program. If introduced, pneumococcal and rotavirus vaccine programs will save 10,796 and 5265 lives, respectively, prevent 94,071 Streptococcus pneumoniae and 94,729 rotavirus cases in children<5 years, and save 3886 and 996 million Ugandan shillings ($2.3 and $0.6 million US dollars), respectively, in direct medical costs annually. At the GAVI price ($0.15/dose), pneumococcal vaccine will be cost-saving and rotavirus vaccine highly cost-effective.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Child, Preschool
  • Cost-Benefit Analysis
  • Humans
  • Infant
  • Models, Statistical
  • Pneumococcal Infections / epidemiology*
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / administration & dosage
  • Pneumococcal Vaccines / economics*
  • Pneumococcal Vaccines / immunology*
  • Rotavirus Infections / epidemiology*
  • Rotavirus Infections / prevention & control
  • Rotavirus Vaccines / administration & dosage
  • Rotavirus Vaccines / economics*
  • Rotavirus Vaccines / immunology*
  • Uganda / epidemiology
  • Vaccination / economics*
  • Vaccination / statistics & numerical data

Substances

  • Pneumococcal Vaccines
  • Rotavirus Vaccines